Two stocks in Healthcare
GSK vs Hikma Pharmaceuticals: profit, growth, debt and price compared
Hikma Pharmaceuticals is stronger on 6 of 7 figures: sales growth, debt, price for its expected profit, dividend, analysts' view and price trend. GSK is stronger on 1: profit margin.
Save both stocks to your watchlist and revisit their latest fundamentals.
| GSKGSK.L | Hikma PharmaceuticalsHIK.L | |
|---|---|---|
| Net margin | Stronger: 13.0% | 11.3% |
| Revenue growth, past year | +4.00% | Stronger: +4.20% |
| Debt to equity | 129.6% | Stronger: 77.1% |
| Forward P/E | 9.9× | Stronger: 9.2× |
| Dividend yield | 3.64% | Stronger: 3.84% |
| Analysts | Hold · 21 | Stronger: Strong buy · 12 |
| From its 200-day average | −0.8% | Stronger: +5.8% |
Share price over the past year
- GSK+5.5%
- Hikma Pharmaceuticals+7.7%
20 Nov 202518 Nov 2026
GSK or Hikma Pharmaceuticals: which is stronger?
- GSK.L
Which is more profitable?
GSK keeps more of each sale as profit: 13.0% against 11.3%.
- HIK.L
Which is growing its sales faster?
Hikma Pharmaceuticals is growing its sales faster: +4.20% over the past year, against +4.00%.
- HIK.L
Which has borrowed less?
Hikma Pharmaceuticals has borrowed less: its debt is 77.1% of what its shareholders own, against 129.6% for GSK.
- HIK.L
Which costs less for the profit it is expected to make?
Hikma Pharmaceuticals costs less for the profit it is expected to make: 9.2× its forward earnings, against 9.9×.
- HIK.L
Which pays more in dividends?
Hikma Pharmaceuticals pays more back in dividends for what a share costs: 3.84% a year, against 3.64%.
- HIK.L
Which do analysts rate higher?
Analysts are warmer on Hikma Pharmaceuticals: Strong buy, against Hold for GSK.
- HIK.L
Which is in the stronger price trend?
Hikma Pharmaceuticals' price is in the stronger trend: 5.8% above its 200-day average, against 0.8% below.
What each company does
GSK.LGSK
GSK plc, together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Reports results on 3 February 2027
HIK.LHikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.